onc201
onc201: developed by 1 company · 4 clinical trials tracked.
onc201 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could onc201 → CMRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CHIMERIX INC (CMRX) H3 K27M-mutant glioma | Phase 3 |
Clinical Trials (4)
A Pilot Study, Open-Label Study of ONC201 for Refractory Meningioma
Primary endpoint: Evaluation of ONC201 concentration in resected meningioma tissue
Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Primary endpoint: Recommended phase 2 dose (RP2D)
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Primary endpoint: Progression-free survival
A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Primary endpoint: Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B Only
Frequently asked questions
Who is developing onc201?
onc201 is being developed by CHIMERIX INC.
How many clinical trials involve onc201?
BioSniper tracks 4 clinical trials involving onc201.